Mizuho Securities Co. Ltd. Takes $84,000 Position in Boston Scientific Co. (NYSE:BSX)

Mizuho Securities Co. Ltd. purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 1,000 shares of the medical equipment provider’s stock, valued at approximately $84,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Saturna Capital Corp lifted its holdings in shares of Boston Scientific by 1.5% during the 3rd quarter. Saturna Capital Corp now owns 26,500 shares of the medical equipment provider’s stock valued at $2,221,000 after buying an additional 400 shares during the period. Aptus Capital Advisors LLC raised its holdings in Boston Scientific by 5.5% in the 3rd quarter. Aptus Capital Advisors LLC now owns 9,969 shares of the medical equipment provider’s stock worth $835,000 after purchasing an additional 520 shares during the period. Aigen Investment Management LP bought a new position in Boston Scientific in the 3rd quarter worth $567,000. Prime Capital Investment Advisors LLC raised its holdings in Boston Scientific by 19.5% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 10,056 shares of the medical equipment provider’s stock worth $843,000 after purchasing an additional 1,638 shares during the period. Finally, Savvy Advisors Inc. bought a new position in Boston Scientific in the 3rd quarter worth $270,000. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on BSX shares. Wells Fargo & Company raised their target price on Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Morgan Stanley raised their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. TD Cowen raised their target price on Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 21st. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Raymond James increased their price target on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, September 4th. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $93.39.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the completion of the sale, the executive vice president now owns 34,748 shares of the company’s stock, valued at $2,913,967.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the transaction, the executive vice president now directly owns 34,748 shares of the company’s stock, valued at $2,913,967.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 309,270 shares of company stock valued at $26,196,718 over the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.5 %

BSX traded up $0.45 on Wednesday, hitting $89.17. The company had a trading volume of 723,858 shares, compared to its average volume of 6,053,401. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a market cap of $131.42 billion, a PE ratio of 73.32, a PEG ratio of 2.61 and a beta of 0.79. Boston Scientific Co. has a 12-month low of $53.56 and a 12-month high of $89.20. The business’s fifty day simple moving average is $84.89 and its 200 day simple moving average is $79.26.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.50 earnings per share. Equities research analysts expect that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.